ZAMMSA Affirms Non-Involvement in Recalled Metformin
The Zambia Medicines Medical Supplies Agency (ZAMMSA) has issued an emphatic statement, clarifying that the recently recalled Metformin Tablets were neither procured nor distributed by their organization. The statement comes in response to the recall initiated by the Zambia Medicines Regulatory Authority (ZAMRA) on December 10th, 2023.
ZAMRA’s recall specifically targeted Metformin Tablets 500 Milligrams Batch number KBT018, supplied by Yash Pharmaceuticals and manufactured by Bliss GVS Pharma PVT Limited of India.
In an official communication, Bradley Chingobe, Senior Manager of Corporate Communications at ZAMMSA, underscored that their agency had no involvement with this particular batch.
“We want to make it abundantly clear that the Metformin Tablets subject to the recall were not part of our procurement and distribution channels,” stated Mr. Chingobe.
He highlighted ZAMMSA’s existing long-standing framework contract with reputable suppliers for the same drug, expressing confidence in the conformity of Metformin procured, stored, and distributed under their purview.
Mr. Chingobe assures the public that all Metformin dispensed by ZAMMSA adheres to rigorous quality control measures.
“All medicines procured by ZAMMSA undergo a pre-distribution Quality Control assessment by ZAMRA, in accordance with our standard operating procedures. The safety of the public remains our top priority,” he added.
As a key player in the healthcare supply chain, Mr. Chingobe underscored ZAMMSA’s commitment to providing safe, cost-effective, and high-quality medicines and medical supplies to the nation. The agency encouraged the public to trust in the safety of the Metformin distributed by ZAMMSA.
